Portfoliotracker

Minerva Neurosciences, Inc.

NERV · NASDAQCM · Healthcare Biotechnology

2,200 $
▼ −0,100 (−4,35 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:51
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score– Market cap166 mil. $ P/E– Forward P/E-5,2 P/S– P/B– EV/EBITDA– Dividend yield– FCF yield– EPS-32,36 $ Net margin0,0 % Return on equity– Beta0,01 Debt / equity–
52-week range 1,96 to 8,80
3-month average volume0,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Employees
7
Country
United States
Fiscal year end
31. 12.
Data since
1. 7. 2014

Explore further

Similar companies CTMXCRVS

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account